Pancreatic Cancer – Unmet Need – Detailed, Expanded Analysis (US/EU)
Pancreatic cancer is a difficult-to-treat malignancy, with dismal survival outcomes. First-line treatment of metastatic disease is limited to chemotherapy-based regimens such as FOLFIRINOX and Abraxane with gemcitabine; these therapies offer only modest survival benefits, highlighting the substantial unmet need for more-effective therapies. Targeted therapies such as Tarceva (Roche) and Lynparza maintenance therapy (AstraZeneca) are also approved to treat pancreatic cancer. In this report, we evaluate the performance of key drugs based on user-defined drug attributes and the impact of these attributes on physicians’ prescribing behavior. We also explore attributes that will favor the uptake of novel therapies for this patient population.
QUESTIONS ANSWERED
- What treatment drivers and goals are most likely to influence the choice of therapy for locally advanced or metastatic pancreatic cancer?
- What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
- What are the prevailing areas of unmet need and opportunity in locally advanced and metastatic pancreatic cancer?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European oncologists for a new treatment for first-line locally advanced or metastatic pancreatic cancer?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in July 2021
Key companies: Celgene, AstraZeneca, Roche, Ipsen / Servier
Key drugs: Abraxane, Onivyde, Tarceva, Lynparza, gemcitabine, 5-FU / leucovorin, FOLFIRINOX
Table of contents
- Pancreatic Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive Summary
- Unmet Need - Locally Advanced or Metastatic Pancreatic Adenocarcinoma - Executive Summary - October 2021
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Regimens for Locally Advanced and Metastatic Pancreatic Cancer and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Pancreatic Cancer
- Importance of Efficacy Attributes to Prescribing Decisions in Pancreatic Cancer: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Pancreatic Cancer: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Pancreatic Cancer: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Pancreatic Cancer: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Pancreatic Cancer: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Prostate Cancer: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Prostate Cancer: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Prostate Cancer: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Pancreatic Cancer: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Pancreatic Cancer: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Pancreatic Cancer: United States
- Overall Performance of Key Therapies for Pancreatic Cancer: Europe
- Mean Overall Performance of Key Therapies for Pancreatic Cancer: United States and Europe
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Pancreatic Cancer Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Surveyed Medical Oncologistsu2019 Satisfaction With the Performance of Key Therapies for Pancreatic Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Medical Oncologistsu2019 Satisfaction With the Performance of Key Therapies for Pancreatic Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Pancreatic Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Pancreatic Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Pancreatic Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Pancreatic Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Pancreatic Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Pancreatic Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Pancreatic Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Pancreatic Cancer: Europe
- Key Findings: Unmet Need in Locally Advanced or Metastatic Pancreatic Adenocarcinoma and Related Indications
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Pancreatic Cancer and Related Indications: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Pancreatic Cancer and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Pancreatic Cancer Market and Emerging Therapy Insights
- Opportunity: A Novel Therapy Offering a Substantial Overall Survival Benefit
- Opportunity: A Novel Therapy With a Better Safety and Tolerability Profile
- Opportunity: A Novel Therapy With a Predictive Biomarker of Therapy Response
- Areas of Opportunity in the Pancreatic Cancer Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Assigned Prohibitions for the Conjoint Module
- Attribute Importance and Part-Worth Utilities
- Pancreatic Cancer Target Product Profile: Attribute Importance
- Median Overall Survival
- Median Progression-Free Survival
- Objective Response Rate
- Incidence of Grade 3/4 Neutropenia
- Incidence of Grade 3/4 Fatigue
- Incidence of Grade 3/4 Diarrhea
- Price per 28-Day Cycle
- Conjoint Analysis-Based Simulation of a Market Scenario
- First-Line Metastatic Pancreatic Cancer Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- First-Line Metastatic Pancreatic Cancer Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- First-Line Metastatic Pancreatic Cancer Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Bibliography
- Executive Summary
Rajashri Lella, M.Pharm., is a research associate on the Oncology team at Clarivate. She performs secondary market research, which includes patent research and pricing for major pharmaceutical markets covering multiple oncology indications. She previously worked on the Oncology Clinical Trial Monitor. Ms. Lella completed a master’s degree in pharmaceutical quality assurance at Manipal Academy of Higher Education in India.